Metrics to compare | ABVC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABVCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.8x | −3.6x | −0.2x | |
PEG Ratio | −0.10 | 0.03 | 0.00 | |
Price/Book | 1.7x | 2.8x | 2.6x | |
Price / LTM Sales | - | 12.5x | 2.6x | |
Upside (Analyst Target) | - | 142.6% | 76.9% | |
Fair Value Upside | Unlock | 10.0% | 14.9% | Unlock |
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.